menu
    • menu
    [{"orgOrder":0,"company":"Long Grove Pharmaceuticals","sponsor":"Nevakar","pharmaFlowCategory":"D","therapeuticArea":"Cardiology\/Vascular Diseases","country":"","productType":"Small molecule","year":"2023","type":"Licensing Agreement","leadProduct":"Norepinephrine Bitartrate","moa":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved","graph3":"Long Grove Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Long Grove Pharmaceuticals \/ Long Grove Pharmaceuticals","highestDevelopmentStatusID":"12","companyTruncated":"Long Grove Pharmaceuticals \/ Long Grove Pharmaceuticals"}]

    Find Clinical Drug Pipeline Developments & Deals by Long Grove Pharmaceuticals

    Menu

    Long Grove Pharmaceuticals

    EVENTS

    • Webinars & Exhibitions

    DIGITAL CONTENT

    DEVELOPMENTS

    FINISHED DOSAGE FORMULATIONS

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Long Grove Pharmaceuticals

                            U.S.A arrow
                            Pharmtech & Ingredients
                            Not Confirmed

                            Long Grove Pharmaceuticals

                            U.S.A arrow
                            Pharmtech & Ingredients
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Norepinephrine Bitartrate

                            Therapeutic Area : Cardiology/Vascular Diseases

                            Study Phase : Approved

                            Recipient : Nevakar

                            Deal Size : Undisclosed

                            Deal Type : Licensing Agreement

                            DEALS_DEV arrow-down

                            Long Grove Pharmaceuticals Secures Commercial Rights to an Essential Critical Care Medication

                            Details : Under the agreement, Long Grove Pharmaceuticals in-licensed Norepinephrine Bitartrate in 0.9% Sodium Chloride premix formulation, indicated to raise blood pressure in adult patients with severe, acute hypotension, from Nevakar Injectables.

                            Brand Name : NVK004

                            Molecule Type : Small molecule

                            Upfront Cash : Undisclosed

                            May 04, 2023

                            Lead Product(s) : Norepinephrine Bitartrate

                            Therapeutic Area : Cardiology/Vascular Diseases

                            Highest Development Status : Approved

                            Recipient : Nevakar

                            Deal Size : Undisclosed

                            Deal Type : Licensing Agreement

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth